Clozapine: neuroleptic-induced EPS and tardive dyskinesia
β Scribed by Daniel E. Casey
- Publisher
- Springer
- Year
- 1989
- Tongue
- English
- Weight
- 863 KB
- Volume
- 99
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
β¦ Synopsis
Clozapine has had a uniquely favorable motor system side effect profile since its initial evaluations. This has been convincingly corroborated by many double blind, single blind, and open studies treating acute and chronic psychosis. The acute extrapyramidal syndromes of dystonia, akathisia and parkinsonism infrequently occur, whereas these syndromes develop in up to 75% of patients receiving traditional neuroleptics. Tardive dyskinesia can be suppressed with higher doses of clozapine given over extended periods. However, an antipsychotic effect can be achieved in many patients at doses below the dyskinesia suppressing level. There is no established causative relationship between clozapine and tardive dyskinesia, but there is a theoretical basis that this may occur. Preliminary data suggest clozapine has mild antiparkinsonian effects as well as efficacy in controlling dopamine agonist-induced psychosis without aggravating parkinsonism. A much wider use of clozapine will further characterize the magnitude of differences compared to other neuroleptics, and identify additional indications for this special compound.
π SIMILAR VOLUMES
Using a liquid chromatographic assay, we measured serum neuroleptic concentrations in eight middle-aged or elderly female inpatients with tardive dyskinesia (TD) and eight controls. All 16 patients were receiving either thioridazine or mesoridazine at stable doses. TD patients were found to have a s
A video-controlled multicenter study with 0 chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden ## Nordic Dyskinesia Study Group The Nordic Dyskinesia Study Group consists of the following: Participating centers.